PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8631193

Optical immunosensors.

S Y Rabbany·B L Donner·F S Ligler
View original source ↗Export metadata ↓

Abstract

The development of biochemical detection systems that use antibodies as the recognition element, also known as immunosensors, has generated considerable interest from science and industry alike. This is due to the practically inexhaustible number of applications for which such a technology could conceivable lend itself, such as medicine, process control, and environmental monitoring. The potentially high sensitivity of such systems makes them ideal for situations where the utmost speed and accuracy are demanded. Moreover, there is theoretically no limit to the chemical and biological moieties for which an immunosensor can be manufactured. This critical review emphasizes both the biological and transduction aspects of optical immunosensors. The basic concepts of antibody-antigen interactions in solution are reviewed, and factors affecting the kinetics at the solid-liquid interface are characterized. In addition, the aspects of reagent immobilization, inherent to immunosensor design, are discussed. Finally, a comprehensive overview describing the mechanisms, advantages, and shortcomings of several immunosensing formats such as fiber-optic, planar waveguide, surface plasmon resonance, and continuous-flow immunosensor is presented. The future of these sensors, we well as the integration of fluorescence lifetime sensing and fluorescent polarization technologies with immunosensing technologies, is contemplated, posing the question: What place will immunosensors secure in tomorrow's market?

Explore related subjects

Antigen-Antibody ReactionsBiosensing TechniquesElectrochemistryFluorescence Polarization ImmunoassayImmunoassayOptics and PhotonicsReproducibility of ResultsSensitivity and SpecificityJournal ArticleResearch Support, U.S. Gov't, Non-P.H.S.Review

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Y Rabbany, B L Donner, F S Ligler. 1994. Optical immunosensors.. https://pubmed.ncbi.nlm.nih.gov/8631193/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Thermodynamic and kinetic analysis of the interaction between hepatitis B surface antibody and antigen on a gold electrode modified with cysteamine and colloidal gold via electrochemistry.

Hepatitis B surface antibody (HBsAb) was immobilized to the surface of a gold electrode modified with cysteamine and colloidal gold as matrices to detect hepatitis B surface antigen (HBsAg). Differential pulse voltammetry (DPV) method was used for the investigation of the specific interaction between the immobilized HBsAb and HBsAg in solution, which was followed as a change of peak current in DPV with time. With the modified gold electrode, the differences in affinity of HBsAb with HBsAg at the temperatures of 37 and 40 degrees C were easily distinguished and the kinetic rate constants (k(ass) and k(diss)) and kinetic affinity constant K were determined from the curves of current versus time. In addition, the thermodynamic constants, DeltaG, DeltaH and DeltaS, of the interaction at 37 degrees C were calculated, which were -56.65, -64.54 and -25.45 kJ mol(-1), respectively.

Antigen-Antibody Reactions↗
PubMed2007

Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.

In order to describe the haemostatic role of a variation in inhibitor reactivity with different factor VIII (FVIII) concentrates, we have compared inhibitor titres against a panel of FVIII concentrates and correlated titre with the capacity to inhibit thrombin generation. Three plasma-derived concentrates were tested in vitro in mixing experiments with inhibitor plasmas from 11 patients with severe haemophilia A: Fanhdi, which contains von Willebrand factor (VWF) with a final ratio of approximately 1:1 (VWF IU per IU FVIII:C); Haemate-P with a ratio of 2.5:1 and Hemofil-M containing only trace amounts of VWF. In addition, the recombinant FVIII concentrate Kogenate Bayer containing no VWF was included. Inhibitor titres and the capacity to generate thrombin were measured. A statistically significant difference in measured titres was found with the highest titres recorded against Hemofil-M. The inhibitor titres needed to inhibit 50% maximum thrombin generation were the lowest for Kogenate Bayer and the highest and similar for Fanhdi and Haemate-P with intermediate titres needed for inhibition of Hemofil-M. In this study, the thrombin generation assay provides additional indications for the role of VWF in the treatment of patients with inhibitors. The VWF-containing concentrates Fanhdi and Haemate-P, added to FVIII-deficient plasma with the presence of inhibitor, generate more thrombin than do the purified concentrates Hemofil-M and Kogenate Bayer.

Antigen-Antibody Reactions↗